Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts
Baxter
McKinsey
Mallinckrodt
McKesson

Last Updated: May 27, 2022

BEVYXXA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Bevyxxa, and what generic alternatives are available?

Bevyxxa is a drug marketed by Portola Pharms Inc and is included in one NDA. There are five patents protecting this drug.

This drug has sixty-eight patent family members in twenty-six countries.

The generic ingredient in BEVYXXA is betrixaban. Additional details are available on the betrixaban profile page.

DrugPatentWatch® Generic Entry Outlook for Bevyxxa

Bevyxxa was eligible for patent challenges on June 23, 2021.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 29, 2031. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Try it Free

Drug patent expirations by year for BEVYXXA
Drug Prices for BEVYXXA

See drug prices for BEVYXXA

DrugPatentWatch® Estimated Generic Entry Opportunity Date for BEVYXXA
Generic Entry Date for BEVYXXA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
CAPSULE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for BEVYXXA

BEVYXXA is protected by six US patents and one FDA Regulatory Exclusivity.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of BEVYXXA is See Plans and Pricing.

This potential generic entry date is based on patent See Plans and Pricing.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting BEVYXXA

Pharmaceutical salts and polymorphs of a factor Xa inhibitor
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Unit dose formulations and methods of treating thrombosis with an oral factor Xa inhibitor
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: INHIBITING COAGULATION

Methods of using crystalline forms of a salt of a factor Xa inhibitor
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT)

Methods of using crystalline forms of a salt of a factor Xa inhibitor
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: PROPHYLAXIS OF VENOUS THROMBOSIS

Methods of synthesizing factor Xa inhibitors
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Pharmaceutical salts and polymorphs of a factor Xa inhibitor
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: PROPHYLAXIS OF PULMONARY EMBOLISM

FDA Regulatory Exclusivity protecting BEVYXXA

NEW CHEMICAL ENTITY
Exclusivity Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Portola Pharms Inc BEVYXXA betrixaban CAPSULE;ORAL 208383-001 Jun 23, 2017 DISCN Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Portola Pharms Inc BEVYXXA betrixaban CAPSULE;ORAL 208383-001 Jun 23, 2017 DISCN Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Portola Pharms Inc BEVYXXA betrixaban CAPSULE;ORAL 208383-002 Jun 23, 2017 DISCN Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Portola Pharms Inc BEVYXXA betrixaban CAPSULE;ORAL 208383-002 Jun 23, 2017 DISCN Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Portola Pharms Inc BEVYXXA betrixaban CAPSULE;ORAL 208383-002 Jun 23, 2017 DISCN Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Portola Pharms Inc BEVYXXA betrixaban CAPSULE;ORAL 208383-001 Jun 23, 2017 DISCN Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for BEVYXXA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Portola Pharms Inc BEVYXXA betrixaban CAPSULE;ORAL 208383-001 Jun 23, 2017 See Plans and Pricing See Plans and Pricing
Portola Pharms Inc BEVYXXA betrixaban CAPSULE;ORAL 208383-002 Jun 23, 2017 See Plans and Pricing See Plans and Pricing
Portola Pharms Inc BEVYXXA betrixaban CAPSULE;ORAL 208383-001 Jun 23, 2017 See Plans and Pricing See Plans and Pricing
Portola Pharms Inc BEVYXXA betrixaban CAPSULE;ORAL 208383-002 Jun 23, 2017 See Plans and Pricing See Plans and Pricing
Portola Pharms Inc BEVYXXA betrixaban CAPSULE;ORAL 208383-002 Jun 23, 2017 See Plans and Pricing See Plans and Pricing
Portola Pharms Inc BEVYXXA betrixaban CAPSULE;ORAL 208383-001 Jun 23, 2017 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for BEVYXXA

When does loss-of-exclusivity occur for BEVYXXA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 07333377
Estimated Expiration: See Plans and Pricing

Canada

Patent: 71502
Estimated Expiration: See Plans and Pricing

Patent: 13963
Estimated Expiration: See Plans and Pricing

China

Patent: 1652136
Estimated Expiration: See Plans and Pricing

Patent: 5193799
Estimated Expiration: See Plans and Pricing

Colombia

Patent: 20933
Estimated Expiration: See Plans and Pricing

Costa Rica

Patent: 914
Estimated Expiration: See Plans and Pricing

Ecuador

Patent: 099501
Estimated Expiration: See Plans and Pricing

European Patent Office

Patent: 01760
Estimated Expiration: See Plans and Pricing

Hong Kong

Patent: 34031
Estimated Expiration: See Plans and Pricing

Israel

Patent: 9219
Estimated Expiration: See Plans and Pricing

Morocco

Patent: 086
Estimated Expiration: See Plans and Pricing

New Zealand

Patent: 8180
Estimated Expiration: See Plans and Pricing

Nicaragua

Patent: 0900145
Estimated Expiration: See Plans and Pricing

Portugal

Patent: 01760
Estimated Expiration: See Plans and Pricing

Russian Federation

Patent: 52484
Estimated Expiration: See Plans and Pricing

Patent: 09126147
Estimated Expiration: See Plans and Pricing

Patent: 12104816
Estimated Expiration: See Plans and Pricing

Singapore

Patent: 201504425S
Estimated Expiration: See Plans and Pricing

South Africa

Patent: 0904758
Estimated Expiration: See Plans and Pricing

South Korea

Patent: 1472765
Estimated Expiration: See Plans and Pricing

Patent: 090107499
Estimated Expiration: See Plans and Pricing

Spain

Patent: 09090
Estimated Expiration: See Plans and Pricing

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering BEVYXXA around the world.

Country Patent Number Title Estimated Expiration
Germany 60115394 See Plans and Pricing
Portugal 2513058 See Plans and Pricing
Spain 2384116 See Plans and Pricing
South Africa 200202117 Inhibitors of factor Xa. See Plans and Pricing
Hong Kong 1051539 See Plans and Pricing
Russian Federation 2008123055 СОЛИ ИНГИБИТОРА ФАКТОРА Ха, СПОСОБ ИХ ПОЛУЧЕНИЯ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ИХ ОСНОВЕ, СПОСОБ ЛЕЧЕНИЯ ТРОМБОЗА И СПОСОБ ИНГИБИРОВАНИЯ КОАГУЛЯЦИИ ОБРАЗЦОВ КРОВИ See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Dow
Boehringer Ingelheim
Medtronic
AstraZeneca
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.